Cost-Utility of Rapid Polymerase Chain Reaction-Based Influenza Testing. for High-Risk Emergency Department Patients

被引:24
|
作者
Dugas, Andrea Freyer [1 ,2 ]
Coleman, Sara [2 ]
Gaydos, Charlotte A. [1 ,2 ,3 ]
Rothman, Richard E. [1 ,3 ]
Frick, Kevin D. [2 ]
机构
[1] Johns Hopkins Univ, Dept Emergency Med, Baltimore, MD 21218 USA
[2] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[3] Johns Hopkins Univ, Div Infect Dis, Dept Med, Baltimore, MD USA
关键词
NEURAMINIDASE INHIBITOR ZANAMIVIR; RANDOMIZED CONTROLLED-TRIAL; B VIRUS-INFECTIONS; UNITED-STATES; ANTIVIRAL THERAPY; OSELTAMIVIR TREATMENT; TREATING INFLUENZA; SEASONAL INFLUENZA; INHALED ZANAMIVIR; DECISION RULE;
D O I
10.1016/j.annemergmed.2013.01.005
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objective: We evaluate the cost-effectiveness of polymerase chain reaction (PCR)-based rapid influenza testing and treatment for influenza in adult emergency department (ED) patients who are at high risk for or have evidence of influenza-related complications. Methods: We developed a cost-utility decision analysis model that assessed adult patients presenting to the ED with symptoms of an acute respiratory infection, who met the Centers for Disease Control and Prevention criteria for recommended antiviral treatment. Analysis was performed from the societal perspective, with incremental comparisons of 4 influenza testing and treatment strategies: treat none, treat according to provider judgment, treat according to results of a PCR-based rapid diagnostic test, and treat all. Results: Treating no patients with antivirals was dominated by all other strategies that increased in both cost and benefit in the following order: treat according to provider judgment, treat according to results of a PCR-based rapid diagnostic test, and treat all. As influenza prevalence increases, treating all patients eventually dominated all other options. Conclusion: The economic benefit of incorporating use of rapid PCR-based influenza testing for ED patients at risk of developing influenza-related complications depends on influenza prevalence; treatment guided by physician diagnosis or rapid testing, and treatment of all patients is more effective and less costly than no treatment.
引用
收藏
页码:80 / 88
页数:9
相关论文
共 50 条
  • [21] Targeting High-Risk Patients for Rapid HIV Testing: Emergency Physicians Are Not Effective and Patients Targeted Are More Frequently Uninsured
    Sankoff, J.
    Valley, M.
    ANNALS OF EMERGENCY MEDICINE, 2008, 52 (04) : S101 - S101
  • [22] Quantitative polymerase chain reaction-based chimerism in bone marrow or peripheral blood to predict acute myeloid leukemia relapse in high-risk patients: results from the KIM-PB prospective study
    Gambacorta, Valentina
    Parolini, Riccardo
    Xue, Elisabetta
    Greco, Raffaella
    Bouwmans, Evelien E.
    Toffalori, Cristina
    Giglio, Fabio
    Assanelli, Andrea
    Stanghellini, Maria Teresa Lupo
    Ambrosi, Alessandro
    Mazzi, Benedetta
    Mulder, Wietse
    Corti, Consuelo
    Peccatori, Jacopo
    Ciceri, Fabio
    Vago, Luca
    HAEMATOLOGICA, 2021, 106 (05) : 1480 - 1483
  • [23] High-risk human papillomavirus infection involving multiple anatomic sites of the female Lower genital tract: a multiplex real-time polymerase chain reaction-based study
    Hui, Yiang
    Manna, Pradip
    Ou, Joyce J.
    Kerley, Spencer
    Zhang, Cunxian
    Sung, C. James
    Lawrence, W. Dwayne
    Quddus, M. Ruhul
    HUMAN PATHOLOGY, 2015, 46 (09) : 1376 - 1381
  • [24] Cost-Utility Analysis of Sacroiliac Joint Fusion in High-Risk Patients Undergoing Multi-Level Lumbar Fusion to the Sacrum br
    Ackerman, Stacey J.
    Deol, Gurvinder S.
    Polly, David W.
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2022, 14 : 523 - 535
  • [25] Point-of-care diagnostic tests for influenza in the emergency department: A cost-effectiveness analysis in a high-risk population from a Canadian perspective
    Mac, Stephen
    O'Reilly, Ryan
    Adhikari, Neill K. J.
    Fowler, Robert
    Sander, Beate
    PLOS ONE, 2020, 15 (11):
  • [26] Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
    Png, May Ee
    Harris, Victoria
    Grabey, Jenna
    Hart, Nigel
    Jani, Bhautesh
    Butler, Daniel
    Carson-Stevens, Andrew
    Coates, Maria
    Cureton, Lucy
    Dobson, Melissa
    Dorward, Jienchi
    Evans, Philip
    Francis, Nick
    Gbinigie, Oghenekome A.
    Hayward, Gail
    Holmes, Jane
    Hood, Kerenza
    Khoo, Saye
    Ahmed, Haroon
    Lown, Mark
    Mckenna, Micheal
    Mort, Sam
    Nguyen-Van-Tam, Jonathan S.
    Rahman, Najib M.
    Richards, Duncan B.
    Thomas, Nicholas P. B.
    van Hecke, Oliver
    Hobbs, Richard
    Little, Paul
    Yu, Ly-Mee
    Butler, Christopher
    Petrou, Stavros
    BRITISH JOURNAL OF GENERAL PRACTICE, 2024, 74 (745): : E570 - E579
  • [27] Comparison of the AmpFire and MA-6000 polymerase chain reaction platforms for high-risk human papillomavirus testing in cervical precancer screening
    Effah, Kofi
    Agbemafle, Isaac
    Essel, Nana Owusu
    Amuah, Joseph Emmanuel
    Kotey, Erasmus Nikoi
    Antwi-Boasiako, Ernest
    Kemawor, Seyram
    Gedzah, Isaac
    Tekpor, Ethel
    Wormenor, Comfort Mawusi
    Atuguba, Bernard Hayford
    Danyo, Stephen
    Akakpo, Patrick Kafui
    JOURNAL OF VIROLOGICAL METHODS, 2023, 316
  • [28] Using Home-Based Community Paramedics to Reduce Emergency Department Utilization by High-Risk Elder Patients
    Cozzi, N.
    Barnhart, C.
    Fennema, P.
    Nelson, G. C.
    Rushton, M. J.
    Chassee, T.
    Jones, J. S.
    ANNALS OF EMERGENCY MEDICINE, 2020, 76 (04) : S4 - S4
  • [29] Intravenous peramivir vs oral oseltamivir in high-risk emergency department patients with influenza: Results from a pilot randomized controlled study
    Hsieh, Yu-Hsiang
    Dugas, Andrea F.
    LoVecchio, Frank
    McBryde, Breana
    Ricketts, Erin P.
    Saliba-Shaw, Kathryn
    Rothman, Richard E.
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2021, 15 (01) : 121 - 131
  • [30] A cost-utility analysis of BRCA1 and BRCA2 testing in high-risk breast cancer patients and family members in Thailand: a cost-effective policy in resource-limited settings
    Lertwilaiwittaya, Pongtawat
    Tantai, Narisa
    Maneeon, Satanun
    Kongbunrak, Sophittha
    Nonpanya, Nongyao
    Hurst, Anna C. E.
    Srinonprasert, Varalak
    Pithukpakorn, Manop
    FRONTIERS IN PUBLIC HEALTH, 2023, 11